Patents by Inventor Kenneth Brooks Low

Kenneth Brooks Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically modified tumor-targeted bacteria with reduced virulence
    Patent number: 7514089
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: April 7, 2009
    Assignee: Vion Pharmaceuticals, Inc.
    Inventors: David Bermudes, Kenneth Brooks Low
  • Genetically modified tumor-targeted bacteria with reduced virulence
    Patent number: 7354592
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purl gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: April 8, 2008
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low
  • Methods for use of genetically modified tumor-targeted bacteria with reduced virulence
    Patent number: 6923972
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: August 2, 2005
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low
  • Genetically modified tumor-targeted bacteria with reduced virulence
    Patent number: 6863894
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: March 8, 2005
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low
  • Vectors for the diagnosis and treatment of solid tumors including melanoma
    Patent number: 6685935
    Abstract: The present invention is directed to the isolation and use of super-infective, tumor-specific vectors that are strains of parasites including, but not limited to bacteria, fungi and protists. In certain embodiments the parasites include, but are not limited to, the bacterium Salmonella spp., such as Salmonella typhimurium, the bacterium Mycobacterium avium and the protozoan Leishmania amazonensis. In other embodiments, the present invention is concerned with the isolation of super-infective, tumor-specific, suicide gene-containing strains of parasites for use in treatment of solid tumors.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: February 3, 2004
    Assignee: Yale University
    Inventors: John M. Pawelek, David Bermudes, Kenneth Brooks Low
  • Methods for use of genetically modified tumor-targeted bacteria with reduced virulence
    Publication number: 20030170276
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Application
    Filed: April 18, 2002
    Publication date: September 11, 2003
    Applicant: Vion Pharmaceuticals, Inc.
    Inventors: David Bermudes, Kenneth Brooks Low
  • Genetically modified tumor-targeted bacteria with reduced virulence
    Publication number: 20030109026
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Application
    Filed: June 27, 2002
    Publication date: June 12, 2003
    Applicant: Vion Pharmaceuticals, Inc.
    Inventors: David Bermudes, Kenneth Brooks Low
  • Genetically modified tumor-targeted bacteria with reduce virulence
    Patent number: 6475482
    Abstract: The invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: November 5, 2002
    Assignee: Vion Pharmaceuticals, Inc.
    Inventors: David Bermudes, Kenneth Brooks Low
  • Genetically modified tumor-targeted bacteria with reduced virulence
    Patent number: 6447784
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: September 10, 2002
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low
  • GENETICALLY MODIFIED TUMOR-TARGETED BACTERIA WITH REDUCED VIRULENCE
    Publication number: 20020026655
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purl gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Application
    Filed: September 8, 1998
    Publication date: February 28, 2002
    Inventors: DAVID BERMUDES, KENNETH BROOKS LOW
  • Vectors for the diagnosis and treatment of solid tumors including melanoma
    Patent number: 6190657
    Abstract: The present invention is directed to the isolation and use of super-infective, tumor-specific vectors that are strains of parasites including, but not limited to bacteria, fungi and protists. In certain embodiments the parasites include, but are not limited to, the bacterium Salmonella spp., such as Salmonella typhimurium, the bacterium Mycobacterium avium and the protozoan Leishmania amazonensis. In other embodiments, the present invention is concerned with the isolation of super-infective, tumor-specific, suicide gene-containing strains of parasites for use in treatment of solid tumors.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: February 20, 2001
    Assignee: Yale University
    Inventors: John M. Pawelek, David Bermudes, Kenneth Brooks Low
  • Genetically modified tumor-targeted bacteria with reduced virulence
    Patent number: 6080849
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: June 27, 2000
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low